Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note released on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock. Other analysts have also issued research reports about the stock. Alliance Global Partners lowered shares of Alimera Sciences from a buy rating to a neutral […]
24.03.2023 - Conference Call to be held Friday, March 31, at 9:00am Eastern TimeATLANTA, March 24, 2023 (GLOBE NEWSWIRE) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, ...
According to Coherent Market Insights, the global eye inflammation treatment market is estimated to be valued at US$ 564.4 Million in 2022 and is expected to
/PRNewswire/ -- The Personal emergency response system market by Distribution Channel, Indication, and Geography - Forecast and Analysis 2023-2027 report has...
The ocular drug delivery system market is experiencing optimistic market growth as a result of an increase in the global burden of the geriatric population, rising cases of various eye disorders